Work

The Immunotherapy Roadmap

Year: 2015

Type: article

Abstract: As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations. Clin Cancer Res; 22(2); 275–6. ©2015 AACR. See related article by Moon et al., p. 436

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-15-2144

Author: James C. Yang

Institution: National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institutes of Health